Long non-coding RNA CCAT1 that can be activated by c-Myc promotes pancreatic cancer cell proliferation and migration

American Journal of Translational Research

Volumn 8, Issue 12, 2016, Pages 5444-5454

  Yu, Qiuyun ^a   Zhou, Xinfeng ^a   Xia, Qing ^a   Shen, Jia ^a   Yan, Jia ^a   Zhu, Jiuting ^a   Li, Xiang ^a   Shu, Ming ^a  

^a Ningbo No2 Hospital   (China)

Author keywords

C Myc; Cell proliferation; LncRNA CCAT1; Metastasis; Pancreatic cancer

Indexed keywords

COLON CANCER ASSOCIATED TRANSCRIPT 1; CYCLIN D1; LONG UNTRANSLATED RNA; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 85007578813     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
2. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S and Mariette C. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081.
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW and Saleh MN. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
4. Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH and Maitra A. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 2013; 19: 4983-4993.
5. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
6. Gutschner T, Hämmerle M, Eißmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M and Groß M. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013; 73: 1180-1189.
7. Davalos V and Esteller M. Unraveling the complex network of interactions between noncoding RNAs and epigenetics in cancer. In: editors. Non-coding RNAs and Cancer. Springer; 2014. pp. 125-148.
8. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH and Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013; 19: 3600-3610.
9. Arora S, Swaminathan SK, Kirtane A, Srivastava SK, Bhardwaj A, Singh S, Panyam J and Singh AP. Synthesis, characterization, and evaluation of poly (D, L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Na-nomedicine 2014; 9: 2933.
10. Cheetham S, Gruhl F, Mattick J and Dinger M. Long noncoding RNAs and the genetics of cancer. Br J Cancer 2013; 108: 2419-2425.
11. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J and Guo Z. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013; 23: 1446-1461.
12. Fan M, Li X, Jiang W, Huang Y, Li J and Wang Z. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med 2013; 5: 1143-1146.
13. Huang L, Liao LM, Liu AW, Wu JB, Cheng XL, Lin JX and Zheng M. Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer. Arch Gynecol Obstet 2014; 290: 717-723.
14. Pang EJ, Yang R, Fu XB and Liu YF. Overex-pression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biol 2015; 36: 2403-2407.
15. Peng W, Gao W and Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol 2014; 31: 1-7.
16. He X, Tan X, Wang X, Jin H, Liu L, Ma L, Yu H and Fan Z. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumor Biol 2014; 35: 12181-12188.
17. Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y and Fang G. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol 2013; 139: 437-445.
18. Franken NA, Rodermond HM, Stap J, Haveman J and Van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-2319.
19. Ding X, Zhou X, Jiang B, Zhao Q and Zhou G. Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells. Mol Med Rep 2015; 12: 4508-4513.
20. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580.
21. Shore AN, Herschkowitz JI and Rosen JM. Noncoding RNAs involved in mammary gland development and tumorigenesis: there’s a long way to go. J Mammary Gland Biol Neo-plasia 2012; 17: 43-58.
22. Chen H, Xu J, Hong J, Tang R, Zhang X and Fang JY. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. Mol Oncol 2014; 8: 1393-1403.
23. Ma M, Chu B, Zhang Y, Weng M, Qin Y, Gong W and Quan Z. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis 2015; 6: e1583.
24. Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y and Fang G. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol 2013; 139: 437-445.
25. Gautschi O, Ratschiller D, Gugger M, Betticher DC and Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant trans-formation. Lung Cancer 2007; 55: 1-14.
26. Li Z, Tian T, Lv F, Chang Y, Wang X, Zhang L, Li X, Li L, Ma W and Wu J. Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. PLoS One 2013; 8: e59203.
27. Biddle A and Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev 2012; [Epub ahead of print].
28. Yang J, Zhang X, Zhang Y, Zhu D, Zhang L, Li Y, Zhu Y, Li D and Zhou J. HIF-2α promotes epithelial-mesenchymal transition through re-gulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. J Exp Clin Cancer Res 2016; 35: 1.
29. Shintani Y, Johnson KR and Wheelock MJ. N-cadherin expression and epithelial-to-mesenchyme transition in pancreatic cancer. Cancer Res 2006; 66: 650-650.
30. Xu Q, Ma J, Lei J, Duan W, Sheng L, Chen X, Hu A, Wang Z, Wu Z and Wu E. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Bio-med Res Int 2014; 2014: 546353-546353.
31. Cole MD and Henriksson M. 25 years of the c-Myc oncogene. Semin Cancer Biol 2006; 16: 241-241.
32. Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC and Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
33. He X, Tan X, Wang X, Jin H, Liu L, Ma L, Yu H and Fan Z. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumour Biol 2014; 35: 12181-12188.